Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 7, 2014, Pages 961-977

  Matera, Maria Gabriella ^a   Rogliani, Paola ^b   Cazzola, Mario ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Aclidinium; Cardiovascular adverse events; Cost effectiveness of long acting muscarinic receptor antagonists; Dual bronchodilation; Emerging long acting muscarinic receptor antagonists; Glycopyrronium; Muscarinic receptor antagonists; Muscarinic receptor subtypes; Tiotropium

Indexed keywords

ACLIDINIUM PLUS FORMOTEROL; AZD 9164; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHF 5259; CORTICOSTEROID; GLYCOPYRRONIUM BROMIDE; GLYCOPYRRONIUM PLUS INDACATEROL; MUSCARINIC RECEPTOR BLOCKING AGENT; OLODATEROL PLUS TIOTROPIUM BROMIDE; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; PT 001; SUN 101; TD 4208; UMECLIDINIUM; UMECLIDINIUM PLUS VILANTEROL; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; DYSPNEA; HUMAN; LUNG FUNCTION; MUCUS; NONHUMAN; QUALITY OF LIFE; REVIEW;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTITUSSIVE AGENTS; DRUG THERAPY, COMBINATION; HUMANS; LUNG; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84899423855     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.899581     Document Type: Review

References (145)

1. Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012;64:450-504
2. Gross NJ, Skorodin MS. Role of the parasympathetic system in airway obstruction due to emphysema. N Engl J Med 1984;311:421-5
3. Matera MG, Page CP, Cazzola M. Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. Trends Pharmacol Sci 2011;32:495-506
4. Matera MG, Cazzola M, Vinciguerra A, et al. A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 1995;8:267-71
5. Cazzola M, Matera MG, Di Perna F, et al. A comparison of bronchodilating effects of salmeterol and oxitropium bromide in stable chronic obstructive pulmonary disease. Respir Med 1998;92:354-7
6. van Noord JA, Bantje TA, Eland ME, et al. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax 2000;55:289-94
7. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002;122:47-55
8. Keating GM. Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease. Drugs 2012;72:273-300
9. Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;7:CD009285
10. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2014.
11. Available from: http://www.goldcopd.org/guidelines-global-strategy-for- diagnosis-management.html [Last accessed 21 February 2014]
12. Chong J, Karner C, Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;9:CD009157
13. Cazzola M, Rogliani P, Segreti A, Matera MG. An update on bronchodilators in Phase I and II clinical trials. Expert Opin Investig Drugs 2012;21:1489-501
14. Cazzola M, Page C, Matera MG. Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulm Pharmacol Ther 2013;26:307-17
15. Buhl R, Banerji D. Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis 2012;7:729-41
16. Compton C, McBryan D, Bucchioni E, Patalano F. The Novartis view on emerging drugs and novel targets for the treatment of chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2013;26:562-73
17. Jones P. Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review. Adv Ther 2013;30:354-68
18. Cazzola M, Page CP, Matera MG. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2013;14:1205-14
19. Karabis A, Lindner L, Mocarski M, et al. Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis. Int J Chron Obstruct Pulmon Dis 2013;8:405-23
20. Bateman ED, Rennard S, Barnes PJ, et al. Alternative mechanisms for tiotropium. Pulm Pharmacol Ther 2009;22:533-42
21. Kistemaker LE, Bos IS, Hylkema MN, et al. Muscarinic receptor subtype-specific effects on cigarette smoke-induced inflammation in mice. Eur Respir J 2013;42:1677-88
22. Buhling F, Lieder N, Kuhlmann UC, et al. Tiotropium suppresses acetylcholine-induced release of chemotactic mediators in vitro. Respir Med 2007;101:2386-94
23. Profita M, Riccobono L, Montalbano AM, et al. In vitro anticholinergic drugs affect CD8+ peripheral blood T-cells apoptosis in COPD. Immunobiology 2012;217:345-53
24. Profita M, Giorgi R, Sala A, et al. Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD. Allergy 2005;60:1361-9
25. Pahl A, Bauhofer A, Petzold U, et al. Synergistic effects of the anti-cholinergic R, R-glycopyrrolate with anti-inflammatory drugs. Biochem Pharmacol 2006;72:1690-6
26. Meurs H, Dekkers BG, Maarsingh H, et al. Muscarinic receptors on airway mesenchymal cells: novel findings for an ancient target. Pulm Pharmacol Ther 2013;26:145-55
27. Doḿinguez-Fandos D, Ferrer E, Puig-Pey R, et al. Effects of aclidinium bromide in a cigarette smoke-exposed guinea pig model of COPD. Am J Respir Cell Mol Biol 2014;50(2):337-46
28. Powrie DJ, Wilkinson TMA, Donaldson GC, et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations of COPD. Eur Respir J 2007;30:472-8
29. Santus P, Buccellati C, Centanni S, et al. Bronchodilators modulate inflammation in chronic obstructive pulmonary disease subjects. Pharmacol Res 2012;66:343-8
30. Pera T, Zuidhof A, Valadas J, et al. Tiotropium inhibits pulmonary inflammation and remodelling in a guinea pig model of COPD. Eur Respir J 2011;38:789-96
31. Asano K, Shikama Y, Shibuya Y, et al. Suppressive activity of tiotropium bromide on matrix metalloproteinase production from lung fibroblasts in vitro. Int J Chron Obstruct Pulmon Dis 2008;3:781-9
32. Asano K, Shikama Y, Shoji N, et al. Tiotropium bromide inhibits TGF-b-induced MMP production from lung fibroblasts by interfering with Smad and MAPK pathways in vitro. Int J Chron Obstruct Pulmon Dis 2010;5:277-86
33. Milara J, Serrano A, Peiro T, et al. Aclidinium inhibits human lung fibroblast to myofibroblast transition. Thorax 2012;67:229-37
34. Milara J, Serrano A, Peiró T, et al. Aclidinium inhibits cigarette smoke-induced lung fibroblast-to-myofibroblast transition. Eur Respir J 2013;41:1264-74
35. Pieper MP, Chaudhary NI, Park JE. Acetylcholine-induced proliferation of fibroblasts and myofibroblasts in vitro is inhibited by tiotropium bromide. Life Sci 2007;80:2270-3
36. Haag S, Matthiesen S, Juergens UR, Racke K. Muscarinic receptors mediate stimulation of collagen synthesis in human lung fibroblasts. Eur Respir J 2008;32:555-62
37. Morcillo EJ, Cortijo J. Mucus and MUC in asthma. Curr Opin Pulm Med 2006;12:1-6
38. Cortijo J, Mata M, Milara J, et al. Aclidinium inhibits cholinergic and tobacco smoke-induced MUC5AC in human airways. Eur Respir J 2011;37:244-54
39. Bos IS, Gosens R, Zuidhof AB, et al. Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison. Eur Respir J 2007;30:653-61
40. Arai N, Kondo M, Izumo T, et al. Inhibition of neutrophil elastase-induced goblet cell metaplasia by tiotropium in mice. Eur Respir J 2010;35:1164-71
41. Annis P, Landa J, Lichtiger M. Effects of atropine on velocity of tracheal mucus in anesthetized patients. Anesthesiology 1976;4:74-7
42. Wanner A. Effect of ipratropium bromide on airway mucociliary function. Am J Med 1986;81:23-7
43. Taylor RG, Pavia D, Agnew JE, et al. Effect of four weeks' high dose ipratropium bromide treatment on lung mucociliary clearance. Thorax 1986;41:295-300
44. Miyata T, Matsumoto N, Yuki H, et al. Effects of anticholinergic bronchodilators on mucociliary transport and airway secretion. Jpn J Pharmacol 1989;51:11-15
45. Hasani A, Toms N, Agnew JE, et al. The effect of inhaled tiotropium bromide on lung mucociliary clearance in patients with COPD. Chest 2004;125:1726-34
46. Holmes PW, Barter CE, Pierce RJ. Chronic persistent cough: use of ipratropium bromide in undiagnosed cases following upper respiratory tract infection. Respir Med 1992;86:425-9
47. Bennett WD, Chapman WF, Mascarella JM. The acute effect of ipratropium bromide bronchodilator therapy on cough clearance in COPD. Chest 1993;103:488-95
48. Lowry R, Wood A, Johnson T, Higenbottam T. Antitussive properties of inhaled bronchodilators on induced cough. Chest 1988;93:1186-9
49. Lowry R, Wood A, Higenbottam T. The effect of anticholinergic bronchodilator therapy on cough during upper respiratory tract infections. Br J Clin Pharmacol 1994;37:187-91
50. van Wyk M, Sommers DK, Snyman JR. Effects of glycopyrrolate on capsaicin-induced cough in normal volunteers treated with captopril. Eur J Clin Pharmacol 1994;46:437-9
51. Dicpinigaitis P, Spinner L, Santhyadka G, Negassa A. Effect of tiotropium on cough reflex sensitivity in acute viral cough. Lung 2008;186:369-74
52. Casaburi R, Briggs DD, Donohue JF, et al. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD. Chest 2000;118:1294-302
53. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:1439-50
54. Worth H, Chung KF, Felser JM, et al. Cardio-and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med 2011;105:571-9
55. Lee TA, Pickard AS, Au DH, et al. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 2008;149:380-90
56. Cazzola M, Calzetta L, Bettoncelli G, et al. Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study. Respir Med 2012;106:249-56
57. Cazzola M, Calzetta L, Matera MG. The cardiovascular risk of tiotropium: is it real? Expert Opin Drug Saf 2010;9:783-92
58. Wise RA, Anzueto A, Cotton D, et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 2013;369:1491-501
59. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54
60. Celli B, Decramer M, Leimer I, et al. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010;137:20-30
61. Dong YH, Lin HH, Shau WY, et al. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease; systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax 2013;68:48-56
62. Verhamme KM, Afonso A, Romio S, et al. Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD. Eur Respir J 2013;42:606-15
63. Jenkins CR, Beasley R. Tiotropium Respimat increases the risk of mortality. Thorax 2013;68:5-7
64. van Noord JA, Cornelissen PJ, Aumann JL, et al. The efficacy of tiotropium administered via Respimat Soft Mist inhaler or HandiHaler in COPD patients. Respir Med 2009;103:22-9
65. Hohlfeld JM, Sharma A, van Noord JA, et al. Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease. J Clin Pharmacol 2013; Epub ahead of print
66. Sentellas S, Ramos I, Albert́i J, et al. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci 2010;39:283-90
67. Sykes DA, Dowling MR, Leighton-Davies J, et al. The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. J Pharmacol Exp Ther 2012;343:520-8
68. Rutten-van Mölken MP, Goossens LM. Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues. Pharmacoeconomics 2012;30:271-302
69. Gani R, Griffin J, Kelly S, Rutten-van Mölken M. Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD. Prim Care Respir J 2010;19:68-74
70. Zaniolo O, Iannazzo S, Pradelli L, Miravitlles M. Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy. Eur J Health Econ 2012;13:71-80
71. Federaal Kenniscentrum voor de Gezondheidszorghttps. Tiotropium in the treatment of chronic obstructive pulmonary disease: health technology assessment. KCE reports 108C.
72. 2007. Available from: https://kce.fgov.be/sites/default/files/page- documents/d20091027320-0-0.pdf [Last accessed 11 March 2014]
73. Mauskopf JA, Baker CL, Monz BU, Juniper MD. Cost effectiveness of tiotropium for chronic obstructive pulmonary disease: a systematic review of the evidence. J Med Econ 2010;13:403-17
74. Hoogendoorn M, Al MJ, Beeh KM, et al. Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial. Eur Respir J 2013;41:556-64
75. Cazzola M, Brusasco V, Centanni S, et al. Project PriMo: sharing principles and practices of bronchodilator therapy monitoring in COPD: a consensus initiative for optimizing therapeutic appropriateness among Italian specialists. Pulm Pharmacol Ther 2013;26:218-28
76. Cazzola M, Molimard M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 2010;23:257-67
77. Cazzola M, Tashkin DP. Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function. COPD 2009;6:404-15
78. van der Molen T, Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J 2012;21:101-8
79. Mahler DA, D'Urzo A, Bateman ED, et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 2012;67:781-8
80. Hodder R, Kesten S, Menjoge S, Viel K. Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids. Int J Chron Obstruct Pulmon Dis 2007;2:157-67
81. Scherr A, Schafroth Török S, Jochmann A, et al. Response to add-on inhaled corticosteroids in COPD based on airway hyperresponsiveness to mannitol. Chest 2012;142:919-26
82. Um SW, Yoo CG, Kim YW, et al. The combination of tiotropium and budesonide in the treatment of chronic obstructive pulmonary disease. J Korean Med Sci 2007;22:839-45
83. Choi J, Na J, Kim Y. The effect of tiotropium and inhaled corticosteroid combination therapy in chronic obstructive pulmonary disease (COPD) and chronic obstructive bronchial asthma (COBA) associated with irreversible pulmonary function [abstract]. Am J Respir Crit Care Med 2007;175:A130
84. Gaebel K, McIvor RA, Xie F, et al. Triple therapy for the management of COPD: a review. COPD 2011;8:206-43
85. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146:545-55
86. Lee TA, Wilke C, Joo M, et al. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease. Arch Intern Med 2009;169:1403-10
87. Rodrigo GJ, Plaza V, Castro-Rodŕiguez JA. Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review. Pulm Pharmacol Ther 2012;25:40-7
88. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials. Lancet 2009;374:695-703
89. Sun SX, Marynchenko M, Banerjee R, et al. Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD. J Med Econ 2011;14:805-15
90. Salmon M, Luttmann MA, Foley JJ, et al. Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther 2013;345:260-70
91. Decramer M, Maltais F, Feldman G, et al. Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients. Respir Physiol Neurobiol 2013;185:393-9
92. Donohue JF, Anzueto A, Brooks J, et al. A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respir Med 2012;106:970-9
93. Trivedi R, Richard N, Mehta R, Church A. Umeclidinium in patients with COPD: a randomised, placebo-controlled study. Eur Respir J 2014;43:72-81
94. Tal-Singer R, Cahn A, Mehta R, et al. Initial assessment of single and repeat doses of inhaled umeclidinium in patients with chronic obstructive pulmonary disease: two randomised studies. Eur J Pharmacol 2013;701:40-8
95. Vehring R, Lechuga-Ballesteros D, Joshi V, et al. Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers. Langmuir 2012;28:15015-23
96. Rennard SI, Fogarty C, Ferguson GT, et al. A novel glycopyrrolate metered dose inhaler formulation demonstrates superior bronchodilator efficacy relative to placebo and comparable efficacy and safety to Spiriva Handihaler in patients with COPD [abstract]. Am J Resp Crit Care Med 2010;181:A4450
97. Orevillo C, St Rose E, Strom S, et al. Glycopyrrolate MDI demonstrates comparable efficacy and safety to tiotropium DPI in a randomised, double-blind, placebo-controlled phase 2b study in patients with COPD [abstract]. Eur Respir J 2011;38(Suppl 55):724s
98. 1) in doses ranging from 36 μ g to 4.6 μ g compared to Atrovent HFA, and placebo in a randomized, double-blind, placebo-controlled phase IIb study in patients with COPD [abstract]. Am J Resp Crit Care Med 2013;187:A4267
99. Singh D, Leaker A, Tutuncu A. Efficacy and safety of nebulized glycopyrrolate (EP-101) for administration using high efficiency nebulizer in patients with COPD [abstract]. Eur Respir J 2011;38(Suppl 55):147s
100. Fogarty C, Kerwin E, Dunn K, et al. The GOLDEN-1 Study: safety and bronchodilatory effects of nebulized glycopyrrolate (EP-101) using high efficiency nebulizer in patients with COPD [abstract]. Eur Respir J 2011;40(Suppl 56):393s
101. Kerwin EM, Fogarty C, Dunn K, et al. Cardiovascular safety of nebulized glycopyrrolate (SUN-101) compared with tiotropium, ipratropium and placebo in patients with COPD [abstract]. Am J Resp Crit Care Med 2013;187:A1483
102. Bjermer L, Bengtsson T, Jorup C, Lötvall J. Local and systemic effects of inhaled AZD9164 compared with tiotropium in patients with COPD. Respir Med 2013;107:84-90
103. Pulido-Rios MT, McNamara A, Obedencio GP, et al. In vivo pharmacological characterization of TD-4208, a novel lung-selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models. J Pharmacol Exp Ther 2013;346:241-50
104. Anonymous. Theravance announces positive results from a phase 2a study of its LAMA candidate, TD-4208, for the treatment of COPD. Available from: http://www.marketwired.com/press-release/Liazon-Private-Benefits-Exchange-Adds- Muscle-to-Executive-Team-1586645.htm [Last accessed 15 December 2013]
105. Anonymous. Theravance announces positive results from phase 2b study 0091 with its LAMA candidate, TD-4208, for the treatment of COPD. Available from: http://investor.theravance.com/releasedetail.cfm?ReleaseID=788832 [Last accessed 15 December 2013]
106. Cazzola M, Lopez-Campos JL, Puente-Maestu L. The MABA approach: a new option to improve bronchodilator therapy. Eur Respir J 2013;42:885-7
107. Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med 2013;1:51-60
108. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013;1:199-209
109. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013;42:1484-94
110. Dahl R, Chapman KR, Rudolf M, et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir Med 2013;107:1558-67
111. Cazzola M, Segreti A, Matera MG. New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol. Drug Des Devel Ther 2013;7:1201-8
112. Anzueto A, Decramer M, Kaelin T, et al. The efficacy and safety of umeclidinium/vilanterol compared with tiotropium or vilanterol over 24 weeks in subjects with COPD [abstract]. Am J Respir Crit Care Med 2013;187:A4268
113. Celli BR, Crater G, Kilbride S, et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest 2014; doi: 10.1378/chest.13-1579
114. Donohue JF, Maleki-Yazdi M, Kilbride S, et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med 2013;107:1538-46
115. Scott LJ, Hair P. Umeclidinium/vilanterol: first global approval. Drugs 2014, doi: 10.1007/s40265-014-0186-8
116. Maltais F, Beck E, Webster D, et al. Four weeks once daily treatment with tiotropium+olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients [abstract]. Eur Respir J 2010;36(Suppl 54):1014s
117. Aalbers R, Maleki-Yazdi MR, Hamilton A, et al. Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat inhaler in patients with COPD [abstract]. Eur Respir J 2012;40:525-526s
118. Gibb A, Yang LP. Olodaterol: first global approval. Drug 2013;73:1841-6
119. Sliwinski P, Perng DW, Chuchalin A, Jones PW. Efficacy and safety of once-daily aclidinium bromide 200 μ g in combination with formoterol in patients with COPD [abstract]. Thorax 2010;65:A136
120. Cazzola M, Rogliani P, Matera MG. Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2013;14:775-81
121. Anonymous. Aclidinium and formoterol combination demonstrates significant lung function improvement in the second pivotal efficacy trial. Available from: http://www.news-medical.net/news/20130502/Aclidinium-and-formoterol- combination-demonstrates-significant-lung-function-improvement-in-the-second- pivotal-efficacy-trial.aspx [Last accessed 15 December 2013]
122. Anonymous. Forest, Almirall report positive results from ACLIFORM/COPD phase III study. Available from: http://drugdelivery.pharmaceutical-business- review.com/news/forest-almirall-report-positive-results-from-acliformcopd-phase- iii-study-020513 [Last accessed 15 December 2013]
123. Reisner C, St Rose E, Strom S, et al. Fixed combination of glycopyrrolate and formoterol MDI (GFF-MDI) demonstrates superior inspiratory capacity (IC) compared to tiotropium DPI (Tio) following 7 days dosing, in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD [abstract]. Eur Respir J 2011;38(Suppl 55):150s
124. Reisner C, Fogarty C, Spangenthal S, et al. Novel combination of glycopyrrolate and formoterol MDI (GFF-MDI) provides superior bronchodilation compared to its components administered alone, tiotropium DPI, and formoterol DPI in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD [abstract]. Am J Respir Crit Care Med 2011;183:A6453
125. Rennard S, Fogerty C, Fischer T, et al. Pearl therapeutics' combination LAMA/LABA MDI (GFF MDI, PT003) provides a significant benefit on home Peak Expiratory Flow Rate (PEFR) and reduces the need for rescue albuterol use compared to its components administered alone, Spiriva Handihaler 18 μ g and Foradil Aerolizer 12 μ g in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD [abstract]. Am J Respir Crit Care Med 2012;185:A2259
126. Reisner C, Gotfried M, Denenberg MB, et al. Low doses of pearl therapeutics' LAMA/LABA combination MDI (GFF MDI, PT003) provide superior bronchodilation compared to components and to open-label Spiriva Handihaler in a randomized, double-blind, placebo-controlled phase IIb study in patients with COPD [abstract]. Am J Respir Crit Care Med 2013;187:A2434
127. Norman P. New dual-acting bronchodilator treatments for COPD, muscarinic antagonists and beta2 agonists in combination or combined into a single molecule. Expert Opin Investig Drugs 2013;22:1569-80
128. Hughes AD, McNamara A, Steinfeld T. Multivalent dual pharmacology muscarinic antagonist and b2 agonist (MABA) molecules for the treatment of COPD. Prog Med Chem 2012;51:71-95
129. Wielders PLML, Ludwig-Sengpiel A, Locantore N, et al. A new class of bronchodilator improves lung function in COPD: a trial with GSK961081. Eur Respir J 2013;42:972-81
130. Cazzola M, Segreti A, Rogliani P. Comparative effectiveness of drugs for chronic obstructive pulmonary disease. Drugs Today (Barc) 2012;48:785-94
131. National Institute for Health and Clinical Excellence. National Clinical Guideline Centre. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. Available from: http://guidance.nice.org. uk/CG101/Guidance/pdf/English [Last accessed 16 December 2013]
132. Wedzicha JA. Choice of bronchodilator therapy for patients with COPD. N Engl J Med 2011;364:1167-8
133. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011;364:1093-103
134. Decramer ML, Chapman KR, Dahl R, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med 2013;1:524-33
135. 1 response to an inhaled long-acting anti-muscarinic in COPD patients. J Pharmacokinet Pharmacodyn 2011;38:105-19
136. Beier J, Kirsten AM, Mróz R, et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled phase IIIb study. COPD 2013;10:511
137. Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009;25:2043-8
138. Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J 2011;37:264-72
139. Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med 2011;105:435-41
140. Beeh KM, Beier J. The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Adv Ther 2010;27:150-9
141. Joos GF, Schelfhout VJ, Pauwels RA, et al. Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients. Respir Med 2010;104:865-72
142. Disse B, Reichl R, Speck G, et al. Ba 679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci 1993;52:537-44
143. Vauquelin G, Charlton SJ. Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br J Pharmacol 2010;161:488-508
144. 2 receptors in acetylcholine-isoproterenol functional antagonism in human isolated bronchus. Am J Physiol Lung Cell Mol Physiol 2002;283:L1125-32
145. Bhavna, Ahmad FJ, Mittal G, et al. Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions. Eur J Pharm Biopharm 2009;71:282-91